argenex (ARGX) Competitors

$806.46 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$807.39 +0.93 (+0.12%)

As of 05/22/2026 04:56 PM Eastern

ARGX vs. SNY, GSK, TAK, TEVA, and ONC

Should you buy argenex stock or one of its competitors? MarketBeat compares argenex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with argenex include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), and BeOne Medicines (ONC). These companies are all part of the "pharmaceutical products" industry.

How does argenex compare to Sanofi?

argenex (NASDAQ:ARGX) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

60.3% of argenex shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

argenex has a net margin of 31.31% compared to Sanofi's net margin of 16.95%. argenex's return on equity of 33.28% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	33.28%	28.16%
Sanofi	16.95%	13.39%	7.58%

In the previous week, argenex and argenex both had 2 articles in the media. Sanofi's average media sentiment score of 0.14 beat argenex's score of 0.00 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanofi	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	11.75	$1.29B	$22.46	35.91
Sanofi	$49.35B	2.19	$8.84B	$3.58	12.37

argenex has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

argenex currently has a consensus price target of $1,017.78, suggesting a potential upside of 26.20%. Sanofi has a consensus price target of $51.00, suggesting a potential upside of 15.15%. Given argenex's stronger consensus rating and higher probable upside, research analysts clearly believe argenex is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

Summary

argenex beats Sanofi on 12 of the 15 factors compared between the two stocks.

How does argenex compare to GSK?

GSK (NYSE:GSK) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

GSK presently has a consensus target price of $53.00, indicating a potential upside of 3.15%. argenex has a consensus target price of $1,017.78, indicating a potential upside of 26.20%. Given argenex's stronger consensus rating and higher possible upside, analysts clearly believe argenex is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

15.7% of GSK shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

GSK has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, argenex has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

GSK has higher revenue and earnings than argenex. GSK is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.42	$7.54B	$3.85	13.35
argenex	$4.25B	11.75	$1.29B	$22.46	35.91

In the previous week, GSK had 4 more articles in the media than argenex. MarketBeat recorded 6 mentions for GSK and 2 mentions for argenex. GSK's average media sentiment score of 0.61 beat argenex's score of 0.00 indicating that GSK is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

argenex has a net margin of 31.31% compared to GSK's net margin of 17.82%. GSK's return on equity of 44.28% beat argenex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
argenex	31.31%	33.28%	28.16%

Summary

argenex beats GSK on 11 of the 17 factors compared between the two stocks.

How does argenex compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

argenex has a consensus price target of $1,017.78, indicating a potential upside of 26.20%. Given argenex's stronger consensus rating and higher possible upside, analysts clearly believe argenex is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

Takeda Pharmaceutical has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, argenex has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

In the previous week, argenex had 1 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 2 mentions for argenex and 1 mentions for Takeda Pharmaceutical. argenex's average media sentiment score of 0.00 beat Takeda Pharmaceutical's score of -0.36 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
argenex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

argenex has a net margin of 31.31% compared to Takeda Pharmaceutical's net margin of 4.31%. argenex's return on equity of 33.28% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.07%	5.49%
argenex	31.31%	33.28%	28.16%

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

argenex has lower revenue, but higher earnings than Takeda Pharmaceutical. argenex is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.82	$1.27B	$0.39	41.60
argenex	$4.25B	11.75	$1.29B	$22.46	35.91

Summary

argenex beats Takeda Pharmaceutical on 15 of the 17 factors compared between the two stocks.

How does argenex compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

In the previous week, Teva Pharmaceutical Industries had 12 more articles in the media than argenex. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 2 mentions for argenex. Teva Pharmaceutical Industries' average media sentiment score of 0.99 beat argenex's score of 0.00 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	10 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

argenex has a net margin of 31.31% compared to Teva Pharmaceutical Industries' net margin of 9.01%. Teva Pharmaceutical Industries' return on equity of 43.53% beat argenex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
argenex	31.31%	33.28%	28.16%

Teva Pharmaceutical Industries presently has a consensus target price of $41.78, indicating a potential upside of 22.75%. argenex has a consensus target price of $1,017.78, indicating a potential upside of 26.20%. Given argenex's stronger consensus rating and higher possible upside, analysts clearly believe argenex is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, argenex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Teva Pharmaceutical Industries has higher revenue and earnings than argenex. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.27	$1.41B	$1.33	25.59
argenex	$4.25B	11.75	$1.29B	$22.46	35.91

Summary

argenex beats Teva Pharmaceutical Industries on 11 of the 17 factors compared between the two stocks.

How does argenex compare to BeOne Medicines?

argenex (NASDAQ:ARGX) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

argenex has higher earnings, but lower revenue than BeOne Medicines. argenex is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	11.75	$1.29B	$22.46	35.91
BeOne Medicines	$5.34B	6.37	$286.93M	$4.47	69.41

argenex currently has a consensus target price of $1,017.78, suggesting a potential upside of 26.20%. BeOne Medicines has a consensus target price of $389.15, suggesting a potential upside of 25.43%. Given argenex's stronger consensus rating and higher possible upside, analysts clearly believe argenex is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, BeOne Medicines had 2 more articles in the media than argenex. MarketBeat recorded 4 mentions for BeOne Medicines and 2 mentions for argenex. BeOne Medicines' average media sentiment score of 0.48 beat argenex's score of 0.00 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

argenex has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

argenex has a net margin of 31.31% compared to BeOne Medicines' net margin of 8.94%. argenex's return on equity of 33.28% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	33.28%	28.16%
BeOne Medicines	8.94%	12.06%	6.69%

60.3% of argenex shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

argenex beats BeOne Medicines on 11 of the 17 factors compared between the two stocks.

Get argenex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARGX vs. The Competition

Export

Metric	argenex	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$49.90B	$3.37B	$6.43B	$12.32B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	35.91	18.91	21.01	25.66
Price / Sales	11.75	329.35	615.84	111.99
Price / Cash	37.80	125.17	43.49	56.67
Price / Book	6.81	7.09	10.37	7.14
Net Income	$1.29B	$24.45M	$3.57B	$335.98M
7 Day Performance	3.89%	5.45%	6.01%	3.56%
1 Month Performance	3.36%	2.43%	3.52%	2.54%
1 Year Performance	37.24%	62.98%	34.13%	35.05%

argenex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARGX argenex	4.3156 of 5 stars	$806.46 flat	$1,017.78 +26.2%	+37.2%	$49.90B	$4.25B	35.91	1,863
SNY Sanofi	4.0677 of 5 stars	$43.54 +2.0%	$51.00 +17.1%	-14.8%	$104.12B	$49.35B	12.16	74,846	Gap Up
GSK GSK	3.1793 of 5 stars	$50.29 +1.2%	$53.00 +5.4%	+32.8%	$100.79B	$43.07B	13.07	66,841	Dividend Cut
TAK Takeda Pharmaceutical	1.8633 of 5 stars	$16.58 -0.2%	N/A	+11.3%	$52.86B	$28.32B	42.50	47,455
TEVA Teva Pharmaceutical Industries	4.6165 of 5 stars	$34.08 -0.6%	$41.78 +22.6%	+100.9%	$39.43B	$17.26B	25.62	33,950

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARGX) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

argenex (ARGX) Competitors

ARGX vs. SNY, GSK, TAK, TEVA, and ONC

How does argenex compare to Sanofi?

Summary

How does argenex compare to GSK?

Summary

How does argenex compare to Takeda Pharmaceutical?

Summary

How does argenex compare to Teva Pharmaceutical Industries?

Summary

How does argenex compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARGX vs. The Competition

argenex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

argenex (ARGX) Competitors

ARGX vs. SNY, GSK, TAK, TEVA, and ONC

How does argenex compare to Sanofi?

Do insiders & institutionals hold more shares of ARGX or SNY?

Is ARGX or SNY more profitable?

Does the media prefer ARGX or SNY?

Which has preferable valuation & earnings, ARGX or SNY?

Which has more volatility and risk, ARGX or SNY?

Do analysts prefer ARGX or SNY?

Summary

How does argenex compare to GSK?

Do analysts recommend GSK or ARGX?

Do insiders and institutionals believe in GSK or ARGX?

Which has more risk and volatility, GSK or ARGX?

Which has better earnings & valuation, GSK or ARGX?

Does the media prefer GSK or ARGX?

Is GSK or ARGX more profitable?

Summary

How does argenex compare to Takeda Pharmaceutical?

Do analysts rate TAK or ARGX?

Which has more risk and volatility, TAK or ARGX?

Does the media prefer TAK or ARGX?

Is TAK or ARGX more profitable?

Do insiders & institutionals believe in TAK or ARGX?

Which has better valuation and earnings, TAK or ARGX?

Summary

How does argenex compare to Teva Pharmaceutical Industries?

Does the media favor TEVA or ARGX?

Is TEVA or ARGX more profitable?

Do analysts rate TEVA or ARGX?

Which has more risk and volatility, TEVA or ARGX?

Do institutionals and insiders believe in TEVA or ARGX?

Which has better earnings and valuation, TEVA or ARGX?

Summary

How does argenex compare to BeOne Medicines?

Which has stronger valuation and earnings, ARGX or ONC?

Do analysts prefer ARGX or ONC?

Does the media refer more to ARGX or ONC?

Which has more risk and volatility, ARGX or ONC?

Is ARGX or ONC more profitable?

Do insiders & institutionals have more ownership in ARGX or ONC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARGX vs. The Competition

argenex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools